EANM Drug Development Committee â Activity Report
EANM Drug Development Committee â Activity Report
EANM Drug Development Committee â Activity Report
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>EANM</strong> TG&C ACTIVITY MATRIX<br />
FOR THE PERIOD 11/2008 – 10/2009<br />
<strong>EANM</strong> <strong>Drug</strong> <strong>Development</strong> <strong>Committee</strong> – <strong>Activity</strong> <strong>Report</strong><br />
COMMITTEE COMPOSITION<br />
Position Name Responsibility<br />
Chair Christer Halldin (Stockholm, SE) To complete the assigned objectives and<br />
communication with the <strong>EANM</strong> Exectutive<br />
<strong>Committee</strong> through the TG&C Coordinator;<br />
CME and congress sessions<br />
Vice Chair Piero Salvadori (Pisa, IT) To assist the Chair as called upon, to act as<br />
Secretary of the <strong>Committee</strong> etc..<br />
Member Jean-Robert Deverre (Orsay, FR) Web page<br />
Member Bengt Långström (Uppsala, SE)<br />
Member Alfons Verbruggen (Leuven, BE)<br />
Preparing and updating guidelines<br />
Preparing and updating guidelines<br />
Member Denis Guilloteau (Tours, FR) Relations with the interest group and national<br />
advisers; relations with DIMI.<br />
Member Heinz Coenen (Juelich, DE) Preparing and updating guidelines<br />
Co-opted<br />
Member –<br />
when given<br />
IAEA Observer: Kishor Solanki<br />
Ludger Dinkelborg (Berlin, DE)<br />
<strong>EANM</strong> Executive Secretariat<br />
Hollandstrasse 14/Mezzanine, A - 1020 Vienna, Austria<br />
Tel: +43-1-2128030, Fax: +43-1-21280309<br />
e-mail: office@eanm.org, http://www.eanm.org
<strong>EANM</strong> TG&C ACTIVITY MATRIX<br />
FOR THE PERIOD 11/2008 – 10/2009<br />
ACTIVITIES DURING THE PERIOD FROM <strong>EANM</strong>’08 MUNICH TO <strong>EANM</strong>’09 BARCELONA<br />
Guidelines:<br />
� Guideline on “Regulations for Radiopharmaceuticals in Early Phase Clinical Studies in the EU”<br />
(published November 2008)<br />
� New Guideline planned on “Principles on Using Imaging on the <strong>Development</strong> of New <strong>Drug</strong>s for the<br />
CNS”<br />
CME / Symposia / Debates to be delivered during <strong>EANM</strong>’09 in Barcelona:<br />
� <strong>EANM</strong>’09 CME Session together with the Radiopharmacy <strong>Committee</strong> on “State of the Art Radio-<br />
Pharmaceutical Production”<br />
� <strong>EANM</strong>’09 CME Session together with the Neuroimaging <strong>Committee</strong> on “Imaging targets<br />
Dementia”<br />
� <strong>EANM</strong>’09 Symposia on “Imaging oncology in drug development” C.Halldin/P.Salvadori<br />
Liaison with related societies (name of society, abbreviation, website):<br />
� DIMI (Diagnostics in Molecular Imaging) EU Center of Excellence program<br />
� ESRR (European Society of Radiopharmacy and Radiopharmaceuticals<br />
Contributions to congresses of related societies / Research activities with related societies:<br />
� A combined course within the DIMI was given in Tours, Nov 3-7, 2008<br />
Other activities:<br />
� Work towards harmonizing regulatory requirements for imaging tracers between the US and the<br />
EU” together with Radiopharmacy C. To support the development of an European eIND similar to<br />
FDA. Give comments to appropriate EMEA drafts.<br />
� Participating in a Roundtable at “Imaging Biomarkers Roundtable, USA, 2009.<br />
<strong>EANM</strong> Executive Secretariat<br />
Hollandstrasse 14/Mezzanine, A - 1020 Vienna, Austria<br />
Tel: +43-1-2128030, Fax: +43-1-21280309<br />
e-mail: office@eanm.org, http://www.eanm.org